查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1496020

全球研究抗體市場：2024-2029 年預測

Global Research Antibodies Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 124 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

2022年研究抗體市值為41.12億美元，預計在預測期內複合年成長率為7.12%，到2029年市場總合規模達到66.53億美元。

研究抗體一詞是指一種用於多種研究目的的蛋白質，包括診斷和有用的研究和發現。由於它們能夠結合特定的原子突變，這些蛋白質被用於細胞研究和開發，以限制和識別特定的細胞。透過蛋白質研究，人們已經能夠評估蛋白質在細胞內如何連接以及它們如何發揮作用。

如今，抗體是研究細胞內蛋白質功能最重要的工具之一。亨廷頓氏症、多發性硬化症和帕金森氏症等神經退化性疾病正在推動神經生物學領域的研究。隨著人口老化和藥物變得稀缺，對研究抗體的需求變得更大。

個人化治療方法的開發、治療方法的進步以及新穎且可行的治療方法的開發等技術正在比以往任何時候都得到更廣泛的探索。根據聯合國發布的《2019年世界人口展望》訊息，未來30年世界人口將加倍，從2019年的77億增至97億，同時世界人口老化加速。 65 歲及以上人口數量將從 2019 年的十分之一（9%）增加到 2050 年的六分之一（16%）。

許多因素正在影響研究抗體市場。例子包括對基因組研究和發現的興趣增加、提高研究可重複性的更高品質的抗體以及生命科學行業研發活動的活性化。在自訂劑量和基於結構的劑量方案需求不斷成長的推動下，全球研究抗體產業預計將在預測期內快速成長。

市場促進因素：

  • 研究和開發的增加預計將推動研究抗體市場的成長。

許多生物製藥和製藥公司研發的顯著增加主要推動了市場的成長。預計利用研究抗體獲得創新的先進診斷和治療產品將推動市場快速擴張。例如，2023 年 12 月，艾伯維 (AbbVie) 和 BigHat Biosciences 宣布合作開發腫瘤學和神經科學領域的下一代治療抗體。 BigHat 利用該公司的 Milliner(TM) 階段、機器學習技術平台套件和高速濕實驗室來指導規劃以及針對眾多修復治療目標的高品質抗體的確定。此外，2023年12月，工業株式會社將與EVQLV, INC.合作，利用EVQLV的人工智慧抗體設計引擎開發創新抗體醫藥品。此次合作的目的是針對小野製藥選定的多個標靶創造新的抗體，並改善創新抗體醫藥品。此次合作也旨在提高工業產品的品質和熟練度。

預計支持產業擴張的另一個數字是政府機構對蛋白質體學和基因組學研究的資助增加。在創新基因組技術的幫助下，人們逐漸認知到導致全球死亡主要原因的遺傳變數。

2024 年 2 月，研究人員從 NIH 精準醫學資料中發現了超過 2.75 億個新發現，這些數據源自於美國衛生研究院「我們所有人」研究計畫的 25 萬名參與者共用的資料。這些資料的一半是從具有非歐洲遺傳血統的參與者獲得的。這項發現為了解遺傳對健康和疾病的影響提供了新途徑，特別是在代表性不足的社區。預計此類市場開拓將在預測期內推動研究抗體市場的成長。

市場限制因素：

  • 抗體開發是一個耗時且成本高昂的過程，可能會阻礙市場發展。

這個過程複雜且耗時，因為抗體的生產必須反映幾個重要因素，例如產生抗體的抗原、其特異性、是單株多株抗體、其影響及其再現性。抗體研究和製造過程中融入了多種創新，包括反應器、層析法、過濾框架以及下游、上游和過濾階段的介質和緩衝液。此類操作的資本投資很高，使得整個過程變得昂貴。

主要進展：

  • 2024 年 3 月 - 吉利德和 Merus 宣布合作發現新型基於抗體的特異性T 細胞接合劑。
  • 2023 年 8 月，生命科學研究工具領域的全球領導者 Abcam plc 已同意以每股 24 美元的現金價格從 Danaher Corporation 收購該公司的所有已發行股票。該證券交易所已獲得 Abcam 和 Danaher 董事會的核准。 Abcam 為藥物發現、生命科學研究和診斷提供高度核准的抗體、試劑、生物標記和檢測檢測法。
  • 2023 年 7 月 - Bio-Techne 收購 Lunaphore Technologies SA，這是一家全自動空間生物學解決方案領域的領先公司。此次收購旨在加強 Lunaphor 作為轉化和臨床研究市場空間生物學領導者的地位。 Lunafore 的設備組合包括 COMET(TM)。 COMET 是一個端到端平台，將組織染色、成像和影像準備步驟整合到高通量儀器中。該平台能夠自動分析每個樣本中的 40 種不同的空間生物標記。 Lunafore 也提供 SPYRE(TM)抗體組合套件和 HORIZON(TM) 影像分析軟體。
  • 2023 年 2 月 - Charles River Laboratories International, Inc. 推出首款 ELISA套件，用於檢測基於 CHO 的生物治療藥物中殘留的宿主細胞蛋白。該套件實現了業界領先的 0.1 ng/mL 靈敏度和特異性以及 90% 的抗體覆蓋率。 AVS Bio 開發的專有雞免疫球蛋白 Y (IgY) 抗體由於鳥類和哺乳動物之間的系統差異而提高了靈敏度和特異性。該套件補充了 Charles River 的生技藥品測試產品，使客戶能夠接受行業專家的測試。
  • 2022 年 10 月 - 羅氏推出 SARS-CoV-2 快速抗體測試 2.0，這是專為照護現場環境中的醫護人員設計的新測試。此測試有助於識別已產生針對 SARS-CoV-2 抗體的患者，並顯示過去的感染或疫苗接種情況。當無法進行實驗室測試或更適合進行指尖採血取樣時，此測試非常有用。醫療保健專業人員還可以檢查患者的抗體狀態，並確定他們是否有先前疫苗接種後殘留的可檢測抗體反應。正在研究該測試以尋找值得關注的新變體。

目錄

第1章簡介

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關利益者的主要利益

第2章調查方法

  • 研究設計
  • 調查過程

第3章執行摘要

  • 主要發現

第4章市場動態

  • 市場促進因素
  • 市場限制因素
  • 波特五力分析
  • 產業價值鏈分析
  • 分析師觀點

第5章 研究抗體的全球市場：依類型

  • 介紹
  • 單株抗體 (mAb)
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 多株抗體(pAb)
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第6章 研究抗體的全球市場：依研究領域

  • 介紹
  • 腫瘤學
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 感染疾病
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 免疫學
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 神經病學
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第7章 全球研究抗體市場：依技術分類

  • 介紹
  • 蛋白質印跡法
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 流式細胞技術
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 酵素免疫分析法測定法 (ELISA)
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力
  • 其他
    • 市場機會和趨勢
    • 成長前景
    • 地域獲利能力

第8章 全球研究抗體市場：按地區分類

  • 介紹
  • 北美洲
    • 按類型
    • 按研究領域
    • 依技術
    • 按國家/地區
  • 南美洲
    • 按類型
    • 按研究領域
    • 依技術
    • 按國家/地區
  • 歐洲
    • 按類型
    • 按研究領域
    • 依技術
    • 按國家/地區
  • 中東/非洲
    • 按類型
    • 按研究領域
    • 依技術
    • 按國家/地區
  • 亞太地區
    • 按類型
    • 按研究領域
    • 依技術
    • 按國家/地區

第9章競爭環境及分析

  • 主要企業及策略分析
  • 市場佔有率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章 公司簡介

  • ProSci Incorporated
  • Thermo Fisher Scientific Inc
  • General Electric
  • Merck KGaA
  • ImmunoPrecise Antibodies Ltd
  • Johnson & Johnson Services, Inc
  • Rockland Immunochemicals, Inc.
  • ACROBiosystems
  • Bio-Rad Laboratories, Inc.
簡介目錄
Product Code: KSI061611694

The global research antibodies market was valued at US$4.112 billion in 2022 and is expected to grow at a CAGR of 7.12% over the forecast period to reach a total market size of US$6.653 billion by 2029.

The term "research antibody" alludes to a sort of protein that's utilized for different research purposes, such as diagnostics and certainly helpful investigation and discovery. As a result of these proteins' capability to enchain to particular atomic variations, they are utilized in cell research and development to confine and recognize particular cells. Through their research studies of proteins, people are way better able to evaluate how proteins are connected and work inside cells.

As of today, antibodies are among the foremost vital apparatuses for examining the work of proteins in cells. Neurodegenerative illnesses such as Huntington's disease, Multiple Sclerosis, and Parkinson's disorder are empowering research in the neurobiological domain. As geriatrics increase and medicines end up scarce, the need for antibodies for investigation work is additionally rising.

The techniques of creating personalized medication, advancing therapeutics, and creating novel and viable treatments are being looked for now more extensively than in previous years. As per the United Nations (UN) information on World Population Prospects for 2019, the global population in the next thirty years will become twofold what it was in 2019, from 7.7 billion to 9.7 billion, and at the same time, the world will age more quickly. The number of individuals over the age of 65 will rise from one in eleven people in 2019 (9%) to one in six by 2050 (16%).

Many factors have affected the market of research antibodies, such as the rising interest in genomics study and discovery, the enhancement of higher-quality antibodies for reproducibility in the study, as well as an increase in R&D activities in the life sciences industry. Fueled by the expanding requirement for custom-made medication and structure-based medication plans, the worldwide industry for research antibodies is anticipated to rise quickly over the forecasted period.

Market Drivers:

  • An increase in research and development is predicted to bolster the research antibodies market growth.

A significant rise in research and development by many biopharmaceutical and pharmaceutical companies is mainly fueling the market growth. The accessibility of innovatively progressed diagnostic and therapeutic items utilizing research antibodies is anticipated to fuel a quick expansion of the market. For instance, in December 2023, AbbVie and BigHat Biosciences declared a research collaboration to create next-generation therapeutic antibodies in oncology and neuroscience. BigHat utilized its Milliner(TM) stage, a suite of machine learning technologies platforms, and a high-speed wet lab to direct the plan as well as the determination of high-quality antibodies for numerous restorative therapeutic targets. Additionally, in in December 2023, Ono Pharmaceutical Co., Ltd. collaborated with EVQLV, INC., to create innovative antibody drugs by using EVQLV's AI-powered product i.e. antibody design engine. The collaboration goal was to create novel antibodies against numerous targets, chosen by Ono, for the improvement of innovative antibody drugs. The partnership also aimed to upgrade the quality and proficiency of Ono's products.

Another figure anticipated to boost industry expansion is an increment in the sum of subsidizing given by government bodies for proteomics and genomics research and investigation. With the assistance of genomic innovative technology, hereditary variables contributing to the major causes of death happening around the world are being recognized.

In February 2024, researchers identified over 275 million new genetic variants in NIH precision medicine data, sourced from data shared by 250,000 participants of the National Institutes of Health's All of Us Research Program. Half of the data comes from non-European genetic ancestry participants. This discovery offers new avenues for understanding genetic influences on health and disease, particularly in underrepresented communities. These market developments will boost the research antibody market growth in the forecast period.

Market Restraints:

  • Developing antibodies is a time-consuming and expensive process that could hamper the market.

The process could be sophisticated and time-consuming to prepare antibodies as it needs reflection of several important factors, such as the antigen against which antibodies will be created, its specificity, monoclonal or polyclonal antibody and affectability, and its reproducibility. Separated from bioreactors and chromatography tars, filtration frameworks, as well as media and buffers for the downstream, upstream, and filtration stages, an assortment of innovations are included in the antibody research production process. Capital investment is high for such operations, making the whole procedure expensive.

Key Developments:

  • March 2024- Gilead and Merus announced a research collaboration to discover novel antibody-based trispecific T-cell engagers. The collaboration is planning to utilize Merus' proprietary Triclonics stage and Gilead's oncology skills to create different preclinical research programs.
  • August 2023- Abcam plc, a global leader in life science research tools, agreed to acquire all outstanding shares of the company from Danaher Corporation for $24.00 per share in cash. The exchange was affirmed by both the Abcam and Danaher boards of directors. Abcam provides exceedingly approved antibodies, reagents, biomarkers, and measures for drug disclosure, life sciences research, and diagnostics. Abcam is getting to work as a standalone working company inside Danaher's Life Sciences fragment.
  • July 2023- Bio-Techne acquired Lunaphore Technologies SA, a leading developer of fully automated spatial biology solutions. The acquisition aims to enhance Lunaphore's spatial biology leadership position in translational and clinical research markets. Lunaphore's instrument portfolio includes COMET(TM), an end-to-end platform with tissue staining, imaging, and image preprocessing steps integrated into a high-throughput instrument. The platform can analyze 40 different spatial biomarkers per sample in each automated run. Lunaphore also offers SPYRE(TM) antibody panel kits and HORIZON(TM) image analysis software.
  • February 2023- Charles River Laboratories International introduced its first ELISA Kit for detecting residual host cell proteins in CHO-based biotherapeutics. The kit achieves industry-leading sensitivity and specificity rates, reaching 0.1 ng/mL and 90% antibody coverage. The unique chicken immunoglobulin Y (IgY) antibodies, developed by AVS Bio, increase sensitivity and specificity due to phylogenetic differences between birds and mammals. The kit complements Charles River's Biologics Testing offering, allowing clients to have industry experts perform the assay.
  • October 2022- Roche introduced the SARS-CoV-2 Rapid Antibody Test 2.0, a new test designed for healthcare professionals in point-of-care settings. This test helps identify patients with developed antibodies against SARS-CoV-2, indicating prior infection or vaccination. It is useful in situations where laboratory testing is unavailable, or finger prick sampling is preferred. Healthcare professionals can also check patients' antibody status and determine if they still have detectable antibody responses from prior vaccination. The test is being investigated against new variants of concern.

Market Segmentation:

Global Research Antibodies Market is segmented and analyzed as below:

By Type

  • Monoclonal Antibodies (mAbs)
  • Polyclonal Antibodies (pAbs)

By Research Area

  • Oncology
  • Infectious Diseases
  • Immunology
  • Neurology
  • Others

By Technology

  • Western Blotting
  • Flow Cytometry
  • Enzyme-linked immunosorbent Assay (ELISA)
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Others
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Others
  • Asia Pacific
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Japan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL RESEARCH ANTIBODIES MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Monoclonal Antibodies (mAbs)
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Polyclonal Antibodies (pAbs)
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL RESEARCH ANTIBODIES MARKET BY RESEARCH AREA

  • 6.1. Introduction
  • 6.2. Oncology
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Infectious Diseases
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Immunology
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Neurology
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL RESEARCH ANTIBODIES MARKET BY TECHNOLOGY

  • 7.1. Introduction
  • 7.2. Western Blotting
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Flow Cytometry
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Enzyme-Linked Immunosorbent Assay (ELISA)
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Others
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness

8. GLOBAL RESEARCH ANTIBODIES MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Research Area
    • 8.2.3. By Technology
    • 8.2.4. By Country
      • 8.2.4.1. United States
        • 8.2.4.1.1. Market Opportunities and Trends
        • 8.2.4.1.2. Growth Prospects
      • 8.2.4.2. Canada
        • 8.2.4.2.1. Market Opportunities and Trends
        • 8.2.4.2.2. Growth Prospects
      • 8.2.4.3. Mexico
        • 8.2.4.3.1. Market Opportunities and Trends
        • 8.2.4.3.2. Growth Prospects
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Research Area
    • 8.3.3. By Technology
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
        • 8.3.4.1.1. Market Opportunities and Trends
        • 8.3.4.1.2. Growth Prospects
      • 8.3.4.2. Argentina
        • 8.3.4.2.1. Market Opportunities and Trends
        • 8.3.4.2.2. Growth Prospects
      • 8.3.4.3. Others
        • 8.3.4.3.1. Market Opportunities and Trends
        • 8.3.4.3.2. Growth Prospects
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Research Area
    • 8.4.3. By Technology
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
        • 8.4.4.1.1. Market Opportunities and Trends
        • 8.4.4.1.2. Growth Prospects
      • 8.4.4.2. Germany
        • 8.4.4.2.1. Market Opportunities and Trends
        • 8.4.4.2.2. Growth Prospects
      • 8.4.4.3. France
        • 8.4.4.3.1. Market Opportunities and Trends
        • 8.4.4.3.2. Growth Prospects
      • 8.4.4.4. Others
        • 8.4.4.4.1. Market Opportunities and Trends
        • 8.4.4.4.2. Growth Prospects
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Research Area
    • 8.5.3. By Technology
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
        • 8.5.4.1.1. Market Opportunities and Trends
        • 8.5.4.1.2. Growth Prospects
      • 8.5.4.2. UAE
        • 8.5.4.2.1. Market Opportunities and Trends
        • 8.5.4.2.2. Growth Prospects
      • 8.5.4.3. Israel
        • 8.5.4.3.1. Market Opportunities and Trends
        • 8.5.4.3.2. Growth Prospects
      • 8.5.4.4. Others
        • 8.5.4.4.1. Market Opportunities and Trends
        • 8.5.4.4.2. Growth Prospects
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Research Area
    • 8.6.3. By Technology
    • 8.6.4. By Country
      • 8.6.4.1. China
        • 8.6.4.1.1. Market Opportunities and Trends
        • 8.6.4.1.2. Growth Prospects
      • 8.6.4.2. India
        • 8.6.4.2.1. Market Opportunities and Trends
        • 8.6.4.2.2. Growth Prospects
      • 8.6.4.3. South Korea
        • 8.6.4.3.1. Market Opportunities and Trends
        • 8.6.4.3.2. Growth Prospects
      • 8.6.4.4. Taiwan
        • 8.6.4.4.1. Market Opportunities and Trends
        • 8.6.4.4.2. Growth Prospects
      • 8.6.4.5. Thailand
        • 8.6.4.5.1. Market Opportunities and Trends
        • 8.6.4.5.2. Growth Prospects
      • 8.6.4.6. Indonesia
        • 8.6.4.6.1. Market Opportunities and Trends
        • 8.6.4.6.2. Growth Prospects
      • 8.6.4.7. Japan
        • 8.6.4.7.1. Market Opportunities and Trends
        • 8.6.4.7.2. Growth Prospects
      • 8.6.4.8. Others
        • 8.6.4.8.1. Market Opportunities and Trends
        • 8.6.4.8.2. Growth Prospects

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. ProSci Incorporated
  • 10.2. Thermo Fisher Scientific Inc
  • 10.3. General Electric
  • 10.4. Merck KGaA
  • 10.5. ImmunoPrecise Antibodies Ltd
  • 10.6. Johnson & Johnson Services, Inc
  • 10.7. Rockland Immunochemicals, Inc.
  • 10.8. ACROBiosystems
  • 10.9. Bio-Rad Laboratories, Inc.